中國同輻(01763.HK):青島原子高通醫藥通過GMP符合性檢查
格隆匯11月24日丨中國同輻(01763.HK)旗下一間於全國中小企業股份轉讓系統上市的附屬公司,原子高科股份有限公司(股份代號:430005)於中國境內發佈,近日,原子高科股份有限公司(以下簡稱:原子高科)控股子公司——青島原子高通醫藥有限公司(以下簡稱:青島原子高通),順利通過山東省食品藥品審評查驗中心藥品GMP符合性檢查,取得鍀即時標記藥品正式投產運營的合規性許可,並計劃於2022年初正式投入運營。
青島原子高通的投產運營,進一步完善了原子高科全國醫藥中心的網絡佈局,為原子高科放藥產業佈局增添了新的力量。青島原子高通將以此為契機,立足"三新一高",不斷加強藥品生產的監督和管理,落實企業安全生產責任,嚴格執行操作規程,嚴把藥品質量標準,忠實踐行"責任、安全、創新、協同"的核心價值觀,為膠東半島地區提供合法合規、質量可靠的放射性藥品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.